GPA33 and adenocarcinoma: The new anti-A33 antibody may prevent the development of mouse CRC lung metastases, and A33-expressing murine adenocarcinoma cells may be destroyed by antibody-dependent cell-mediated cytotoxicity (ADCC) (Murer et al., 2020).